U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30N6O8
Molecular Weight 494.4983
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of BALAPIRAVIR

SMILES

CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N2C=CC(N)=NC2=O)N=[N+]=[N-]

InChI

InChIKey=VKXWOLCNTHXCLF-DXEZIKHYSA-N
InChI=1S/C21H30N6O8/c1-10(2)17(28)32-9-21(25-26-23)15(34-19(30)12(5)6)14(33-18(29)11(3)4)16(35-21)27-8-7-13(22)24-20(27)31/h7-8,10-12,14-16H,9H2,1-6H3,(H2,22,24,31)/t14-,15+,16-,21-/m1/s1

HIDE SMILES / InChI

Molecular Formula C21H30N6O8
Molecular Weight 494.4983
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 1
Optical Activity UNSPECIFIED

R1479 (4′-azidocytidine) is a specific inhibitor of hepatitis C virus (HCV) replication. 4′-azidocytidine triphosphate is an inhibitor of native HCV replicase and recombinant HCV polymerase (NS5B). Balapiravir (R1626) is the tri-isobutyrate ester prodrug of R1479 under clinical development to improve exposure of R1479 upon oral administration.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
Drug as victim

Drug as victim

PubMed

PubMed

TitleDatePubMed
Synthesis and anti-HIV activity of 4'-azido- and 4'-methoxynucleosides.
1992 Apr 17
The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture.
2006 Feb 17
Design, synthesis, and antiviral properties of 4'-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479.
2007 May 1
Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.
2008 Aug
2'-deoxy-4'-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2'-alpha-hydroxyl groups.
2008 Jan 25
Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients.
2008 Jun
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.
2008 May
R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus.
2008 Oct
Amidinoanthracyclines - a new group of potential anti-hepatitis C virus compounds.
2009 Apr
The design, synthesis, and antiviral activity of 4'-azidocytidine analogues against hepatitis C virus replication: the discovery of 4'-azidoarabinocytidine.
2009 Jan 8
Substituted imidazopyridines as potent inhibitors of HCV replication.
2009 May
The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4'-azidocytidine against hepatitis C virus replication: the discovery of 4'-azido-2'-deoxy-2'-fluorocytidine and 4'-azido-2'-dideoxy-2',2'-difluorocytidine.
2009 May 14
Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication.
2010 Apr 22
PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
2010 Aug
2'-Deoxy-2'-spirocyclopropylcytidine revisited: a new and selective inhibitor of the hepatitis C virus NS5B polymerase.
2010 Nov 25
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
2012 Jan-Feb
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.
2014
Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir.
2014 Feb
Patents

Sample Use Guides

The phase 2, double-blind international trial evaluated the optimal treatment regimen of balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in hepatitis C genotype 1 patients. Treatment-naive genotype 1 patients were randomized to one of seven treatment groups in which they received balapiravir 500, 1,000, or 1,500 mg twice daily, peginterferon alfa-2a (40KD) 180 or 90 µg/week and ribavirin 1,000/1,200 mg/day or peginterferon alfa-2a (40KD)/ribavirin. The planned treatment duration with balapiravir was reduced from 24 to 12 weeks due to safety concerns.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Activity is given for R1479. Balapiravir (R-1626) is the tri-isobutyl ester prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479).
R1479 (4'-azidocytidine) is a specific inhibitor of HCV replication in the HCV subgenomic replicon system (IC(50) = 1.28 microM). R1479 showed no effect on cell viability or proliferation of HCV replicon or Huh-7 cells at concentrations up to 2 mM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:14:12 GMT 2023
Edited
by admin
on Fri Dec 15 16:14:12 GMT 2023
Record UNII
VOT0LP7I9K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BALAPIRAVIR
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
R1626
Code English
Balapiravir [WHO-DD]
Common Name English
RO-4588161
Code English
RO4588161
Code English
CYTIDINE, 4'-C-AZIDO-, 2',3',5'-TRIS(2-METHYLPROPANOATE)
Common Name English
R-1626
Code English
balapiravir [INN]
Common Name English
4-AMINO-1-(4-C-AZIDO-2',3',5'-TRI-O-(2-METHYLPROPANOYL)-.BETA.-D-RIBOFURANOSYL)PYRIMIDIN- 2(1H)-ONE
Common Name English
BALAPIRAVIR [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C281
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
NCI_THESAURUS C25995
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
Code System Code Type Description
DRUG BANK
DB12283
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
CAS
690270-29-2
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
WIKIPEDIA
Balapiravir
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
NCI_THESAURUS
C87439
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
INN
8977
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
ChEMBL
CHEMBL550936
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
USAN
WW-123
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
FDA UNII
VOT0LP7I9K
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
SMS_ID
100000155367
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
EVMPD
SUB129425
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
MESH
C530825
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
EPA CompTox
DTXSID40219098
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
PUBCHEM
11691726
Created by admin on Fri Dec 15 16:14:12 GMT 2023 , Edited by admin on Fri Dec 15 16:14:12 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
ACTIVE MOIETY